Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts (NASDAQ:ROIV)

Roivant (ROIV) Q4 2025 earnings call highlights: IMVT-1402 RA data, mosliciguat PH-ILD updates, brepocitinib launch timeline & Moderna settlement—read now.

Read on WOBR AI →